ViiV's Tivicay PD Becomes First HIV Drug Approved for Newborns from Birth

ViiV Healthcare, majority-owned by GSK (NYSE: GSK), won FDA approval for Tivicay PD tablets for oral suspension (dolutegravir) to treat HIV infection in newborns from birth to four weeks weighing at least 2 kg, in combination with other antiretrovirals. The decision extends dolutegravir to the youngest patients, who previously had no approved integrase inhibitor. GSK closed at $52.07 on August 25, up 0.6%.

The approval rests on the IMPAACT 2023 study (NCT05406583), in which 48 HIV-exposed newborns weighing at least 2 kg received Tivicay PD from birth for up to six weeks alongside standard-of-care antiretrovirals to prevent mother-to-child transmission. Pharmacokinetic modeling showed drug levels in newborns matched those tied to efficacy in adults, and the safety profile was consistent with older pediatric and adult patients. Patients must be monitored for liver damage, and immune reconstitution syndrome has been reported with combination antiretroviral therapy. Tivicay PD tablets for oral suspension are not substitutable milligram-for-milligram with Tivicay tablets. The FDA granted the application Priority Review.

Why It Matters

Newborns have been a gap in the HIV arsenal. Tivicay and Tivicay PD were previously approved only for adults and children older than four weeks, leaving the first month of life, the window in which blocking the virus from taking hold matters most, without an integrase inhibitor option. Dolutegravir is a second-generation integrase inhibitor and a cornerstone of global HIV therapy, and ViiV’s Cabenuva long-acting regimen already anchors adolescent and adult treatment.

The label expansion is more a public-health milestone than a near-term financial catalyst for GSK. Pediatric HIV in the U.S. is rare, so the commercial read-through is small. But it closes a real treatment gap and stretches dolutegravir’s franchise across every age group, from prevention through long-acting treatment. We’ve followed ViiV’s HIV work in our coverage of Cabenuva’s adolescent superiority data.

What Happens Next

Watch whether ViiV pursues a newborn label for its long-acting cabotegravir injectables and how quickly global HIV treatment guidelines fold dolutegravir into neonatal protocols. The sNDA is now approved; the practical question is how fast neonatal treatment protocols adopt the dosing.

What It Means for the Trade

The honest framing: this approval is not a reason to buy GSK, and it was never priced as one. U.S. perinatal HIV transmissions number in the dozens per year thanks to prenatal ART screening, so the incremental revenue here rounds to zero against a company that did more than £30 billion in sales. Traders who bought the headline got a public-health story, not an earnings story.

But two second-order angles are worth holding. First, label completeness is a moat. Dolutegravir is locked in a two-horse race with Gilead’s bictegravir for global HIV supremacy, and every age band ViiV covers — now literally from birth — strengthens its negotiating position with national formularies and PEPFAR-style procurement bodies, where Gilead has been chipping away with single-tablet Biktarvy. A birth-to-adult label is a procurement argument, not a price argument.

Second, watch the Neonatal HIV Prevention synergy. IMPAACT 2023 enrolled HIV-exposed newborns — babies born to mothers with HIV — and the study design (dosing from birth alongside prophylaxis) means ViiV now has the PK scaffolding to test cabotegravir in the same window. If long-acting injectables ever extend to neonates, ViiV could offer birth-to-death regimen continuity that no competitor matches. That is a multi-year story, but it is the only path by which this approval becomes financially interesting.

Company and Pipeline Context

GSK’s HIV business runs through ViiV, its majority-owned joint venture with Pfizer and Shionogi, and it is one of the brighter spots in a portfolio still digesting Zantac litigation overhang and respiratory-vaccine execution questions. Dolutegravir in its various forms — Tivicay, the Triumeq and Dovato single-tablet regimens, and the dispersible PD formulation — remains the volume backbone, while Cabenuva (cabotegravir plus rilpivirine) is the margin growth story as monthly-to-every-two-months injectables gain share in the U.S. and Europe.

The competitive clock matters here. Gilead’s Biktarvy is gobbling the U.S. treatment-naive market, and its lenacapavir long-acting pipeline (Sunlenca, plus six-monthly regimens in prevention) pressures ViiV on the convenience frontier. GSK’s counter is breadth across populations and price tiers in low- and middle-income markets, where ViiV’s pediatric franchise and voluntary licensing position are structural advantages. The neonatal label is a small brick in exactly that wall.

Risks and What Could Go Wrong

Adoption risk is the real one. A label is not a protocol: neonatal dosing requires weight-banded suspension preparation, liver-function monitoring in the first weeks of life, and clinician comfort with a drug that until August had never been given at that age. Guideline bodies (DHHS perinatal guidelines, WHO) move on their own timelines, and a cautious “conditional recommendation” would keep uptake slow even in the U.S. In high-burden settings abroad, the >2 kg weight floor and cold-chain suspension handling both bind.

For the stock, the risks are simply that this doesn’t matter — GSK trades on Shingrix, Arexvy, oncology pipeline readouts (B7-H3, GPRC5D entries in multiple myeloma), and Zantac court dates. Any signal from this approval gets washed out. And on a longer horizon, dolutegravir’s patent estate ages into the late-2020s; the franchise defense rests on Cabenuva and the integrase-to-long-acting transition, not on neonatal label additions. Treat this one as a franchise-completeness data point inside a larger ViiV thesis, nothing more.